Medical Pharmacology: Chapter 15: Local Anesthetics -- Module 2: Clinical Pharmacology of Individual Agents, Adjuvants, Toxicology, and Drug Interactions

Chapter 15: Local Anesthetics — Module 2: Clinical Pharmacology of Individual Agents, Adjuvants, Toxicology, and Drug Interactions
Tier: Foundational Recall (16 questions)

1. Both lidocaine and bupivacaine block voltage-gated sodium channels by binding within the channel pore during depolarization. At toxic plasma concentrations, bupivacaine produces cardiovascular collapse that is far more refractory to treatment than lidocaine toxicity at equivalent concentrations. Which of the following correctly identifies the specific kinetic property that accounts for this difference?

A) Bupivacaine has a higher affinity for the inactivated state of the sodium channel than lidocaine, meaning it binds the channel only when the membrane is fully depolarized and cannot bind during the resting state — trapping it in cardiac tissue during systole.
B) Bupivacaine irreversibly inhibits the sodium channel by forming a covalent bond with the phenylalanine residue at the inner vestibule of the channel, whereas lidocaine binding is non-covalent and therefore fully reversible.
C) Bupivacaine blocks cardiac potassium channels (IKr) in addition to sodium channels, prolonging the action potential duration and creating a combined sodium-potassium channel block that is synergistically more difficult to reverse than sodium channel block alone.
D) Bupivacaine dissociates from the cardiac Nav1.5 sodium channel very slowly during diastole — the "fast-in, slow-out" pattern — so blocked channels do not recover between beats and conduction block accumulates with each successive heartbeat; lidocaine dissociates rapidly during diastole ("fast-in, fast-out"), allowing full channel recovery before the next beat.
E) Bupivacaine is more lipid-soluble than lidocaine and therefore accumulates in the phospholipid bilayer of the cardiomyocyte membrane at higher concentrations, creating a membrane-stabilizing effect that persists long after plasma concentrations fall below toxic thresholds.

ANSWER: D

Rationale:

Option D is correct. The critical pharmacokinetic distinction between lidocaine and bupivacaine cardiac toxicity lies in their respective rates of dissociation from the cardiac Nav1.5 sodium channel during diastole — the interval between action potentials when channels are in the resting state. Lidocaine dissociates rapidly enough during diastole that channels recover their excitability before the next depolarization; this "fast-in, fast-out" pattern means that even at elevated plasma concentrations, lidocaine-induced conduction changes are relatively well-tolerated and rapidly reversible. Bupivacaine, by contrast, dissociates so slowly from the channel that a significant fraction of channels remain blocked when the next action potential arrives. With each successive beat, more channels accumulate in the blocked state — a "use-dependent" or "phasic" block — producing progressive QRS complex (QRS) widening, ventricular dysrhythmia, and ultimately cardiovascular collapse. Because the drug remains tightly bound in the channel, standard resuscitation measures including epinephrine and defibrillation are often insufficient; lipid emulsion therapy is required to extract bupivacaine from cardiac tissue.

Option A: Option A is incorrect; while local anesthetics do show preferential binding to inactivated channels (use-dependence), the clinical difference between lidocaine and bupivacaine is not which state they prefer but how quickly they dissociate during diastole.
Option B: Option B is incorrect; bupivacaine binding is reversible, not covalent — the danger is the slow rate of reversal, not permanent alkylation.
Option C: Option C is incorrect; bupivacaine's primary cardiac toxicity mechanism is sodium channel blockade; while some potassium channel effects have been described, these are not the primary mechanism distinguishing its toxicity from lidocaine's.
Option E: Option E is incorrect; while bupivacaine's high lipid solubility does contribute to its membrane partitioning, the clinically relevant mechanism of refractory cardiac toxicity is channel kinetics, not membrane accumulation.

2. An anesthesiologist is planning a femoral nerve block and considering whether to add epinephrine to the local anesthetic solution. She notes that the proportional extension of block duration produced by epinephrine differs substantially between lidocaine and ropivacaine. Which of the following correctly explains this difference and its pharmacologic basis?

A) Ropivacaine possesses intrinsic vasoconstrictive activity mediated through α₁-adrenergic receptors on vascular smooth muscle, which already slows its own systemic absorption from the injection site; epinephrine therefore provides a smaller proportional benefit for ropivacaine (approximately 15–30% duration extension) than for lidocaine, which is intrinsically vasodilatory and relies more heavily on epinephrine-mediated vasoconstriction to slow absorption (approximately 50–100% extension).
B) Ropivacaine is more highly protein-bound than lidocaine and therefore distributes less freely into vascular tissue surrounding the injection site; epinephrine's vasoconstrictive effect acts primarily on vascular uptake of free drug, so its benefit is proportionally smaller for an agent that is already less available to vascular absorption.
C) Lidocaine has a higher pKa than ropivacaine, meaning a larger ionized fraction at physiologic pH; the ionized form is more water-soluble and therefore diffuses more rapidly into the bloodstream, making vasoconstrictive slowing of absorption more pharmacologically meaningful for lidocaine than for the less ionized ropivacaine.
D) Epinephrine extends block duration by a direct neural mechanism — activating α₂-adrenergic receptors on axonal membranes to hyperpolarize nociceptors — and this effect is saturable; ropivacaine already partially occupies α₂ receptors at the injection site, so epinephrine provides less additional α₂ stimulation for ropivacaine-containing blocks than for lidocaine-containing blocks.
E) The difference reflects metabolism rather than absorption: lidocaine is metabolized by hepatic CYP enzymes that are subject to competitive inhibition by epinephrine's metabolic byproducts, prolonging lidocaine's effective half-life; ropivacaine's CYP1A2 pathway is not similarly inhibited, so epinephrine confers no metabolic benefit for ropivacaine.

ANSWER: A

Rationale:

Option A is correct. Ropivacaine is unusual among amide local anesthetics in possessing intrinsic vasoconstrictive activity, mediated through α₁-adrenergic receptor stimulation on vascular smooth muscle at clinically used concentrations. This property means ropivacaine already slows its own absorption from the injection site through vasoconstriction — an effect that is independent of any added epinephrine. Because ropivacaine's baseline absorption is already reduced by this intrinsic vasoconstrictive mechanism, the marginal additional benefit of epinephrine-induced vasoconstriction is smaller, producing approximately 15–30% prolongation of block duration. Lidocaine, by contrast, is intrinsically vasodilatory at the injection site — it tends to increase local blood flow and accelerate its own absorption. Adding epinephrine to lidocaine therefore produces a much more substantial relative effect, extending peripheral nerve block duration by approximately 50–100% by converting lidocaine's vasodilatory baseline to a vasoconstrictive one. This pharmacologic principle has practical implications: epinephrine is considered a more important adjuvant for lidocaine-based blocks than for ropivacaine-based blocks, and maximum dose guidelines for ropivacaine are less dramatically affected by epinephrine than those for lidocaine.

Option B: Option B is incorrect; while ropivacaine protein binding (~94%) is high, it is not substantially different from bupivacaine, and protein binding does not explain the differential epinephrine response between ropivacaine and lidocaine.
Option C: Option C is incorrect; lidocaine's pKa (7.9) is actually lower than ropivacaine's (8.1), meaning lidocaine has a larger free-base fraction at physiologic pH, not a larger ionized fraction; and ionization state does not explain the differential epinephrine response.
Option D: Option D is incorrect; epinephrine's block-prolonging mechanism at peripheral nerves is primarily vasoconstriction, not direct α₂ neural hyperpolarization (that is the mechanism of clonidine and dexmedetomidine), and ropivacaine does not occupy α₂ receptors.
Option E: Option E is incorrect; epinephrine does not inhibit CYP enzymes, and its block-prolonging effect is pharmacokinetic (absorption rate), not metabolic.

3. Three local anesthetics are being compared for onset speed. Their pKa values are: chloroprocaine 8.7, lidocaine 7.9, and mepivacaine 7.6. All three are injected at the same site under identical clinical conditions. Which of the following correctly ranks their onset speed from fastest to slowest, and correctly explains the mechanism?

A) Chloroprocaine fastest, lidocaine intermediate, mepivacaine slowest — because higher pKa increases lipid solubility, and greater lipid solubility produces faster membrane penetration regardless of ionization state.
B) Mepivacaine fastest, chloroprocaine slowest, lidocaine intermediate — because lower pKa agents are more rapidly hydrolyzed by plasma pseudocholinesterase, creating a steeper concentration gradient from plasma into nerve tissue that accelerates onset.
C) Mepivacaine fastest, lidocaine intermediate, chloroprocaine slowest — because at physiologic pH of 7.4, the agent with the lowest pKa has the largest fraction in the unionized free-base form, and the unionized form is the membrane-permeable species that diffuses across nerve sheaths and axonal membranes to reach sodium channels; chloroprocaine's pKa of 8.7 leaves less than 5% in the free-base form at pH 7.4, substantially slowing its onset despite its other properties.
D) All three agents have equivalent onset speed because onset is determined primarily by total dose injected, not by pKa; higher doses of chloroprocaine compensate for its less favorable ionization equilibrium.
E) Chloroprocaine fastest, mepivacaine slowest, lidocaine intermediate — because chloroprocaine's ester-class structure is hydrolyzed at the nerve membrane, releasing the free acid directly into the axoplasm and bypassing the need for transmembrane diffusion that limits onset for amide agents.

ANSWER: C

Rationale:

Option C is correct. Onset speed of local anesthetics at a given injection site is primarily determined by the fraction of drug existing in the unionized free-base form at physiologic pH, which is governed by the Henderson-Hasselbalch relationship. At pH 7.4, an agent with a pKa of 7.6 (mepivacaine) has the largest unionized fraction — approximately 61% — producing the fastest diffusion across the lipid nerve sheath and axonal membrane. Lidocaine (pKa 7.9) has a smaller unionized fraction at pH 7.4 — approximately 24% — producing intermediate onset speed. Chloroprocaine (pKa 8.7) has the smallest unionized fraction at pH 7.4 — less than 5% — meaning the overwhelming majority of drug is in the ionized, membrane-impermeant form, which substantially slows diffusion to sodium channels and produces the slowest onset of the three. It is worth noting that despite having the slowest onset by pKa prediction, chloroprocaine is used clinically for epidural anesthesia where its exceptionally rapid systemic clearance (pseudocholinesterase half-life under 60 seconds) makes it uniquely safe at the high doses needed to compensate for its less favorable onset kinetics.

Option A: Option A is incorrect; higher pKa does not increase lipid solubility — pKa (ionization) and lipid solubility (membrane partitioning of the free base) are independent physicochemical properties.
Option B: Option B is incorrect; pKa does not determine the rate of pseudocholinesterase hydrolysis; pseudocholinesterase metabolizes ester agents (chloroprocaine, procaine, tetracaine) and does not act on amide agents at the nerve membrane.
Option D: Option D is incorrect; while total dose and concentration do influence onset (the nerve will be blocked faster with a higher concentration), pKa is a significant and independent determinant of onset at any given concentration, and the question controls for identical conditions.
Option E: Option E is incorrect; chloroprocaine is not hydrolyzed at the nerve membrane to release the free acid — its plasma hydrolysis occurs in the systemic circulation after absorption, not at the site of nerve contact.

4. Bupivacaine 0.5% is routinely used for epidural surgical anesthesia including cesarean delivery, yet bupivacaine 0.75% is formally contraindicated for obstetric epidural use. Both concentrations share the same molecule with identical channel-binding kinetics. Which of the following best explains why the concentration difference produces such a dramatically different safety classification in the obstetric setting?

A) The 0.75% formulation contains a preservative (methylparaben) not present in the 0.5% formulation; it is this preservative, not the bupivacaine itself, that produces the severe cardiovascular toxicity associated with the higher-concentration preparation.
B) Bupivacaine at 0.75% concentration exceeds the critical micellar threshold at which the drug self-aggregates into lipid micelles; these micelles are taken up by cardiomyocytes through endocytosis and release concentrated drug intracellularly, bypassing the normal concentration-dependent absorption barrier.
C) Bupivacaine 0.75% produces a higher degree of thoracic sympathetic blockade than 0.5% when used epidurally, resulting in more severe maternal hypotension; the cardiac compromise from sympathectomy-induced hypotension is synergistic with bupivacaine's direct cardiac effects, making the combined toxicity disproportionately severe.
D) At 0.75% concentration, bupivacaine undergoes a conformational change that increases its affinity for cardiac Nav1.5 channels by approximately threefold compared to 0.5% bupivacaine; this concentration-dependent pharmacodynamic shift is not seen with dilute epidural solutions.
E) The 0.75% and 0.5% solutions are pharmacodynamically identical when used correctly, but the 0.75% concentration produces a substantially higher total milligram bolus if accidentally injected intravascularly — delivering lethal bupivacaine concentrations to the heart before clinical detection of misplacement is possible; the 1984 FDA contraindication reflects the principle that the highest available concentration of a potent cardiotoxic agent must not be used where inadvertent intravascular injection is both probable and catastrophic.

ANSWER: E

Rationale:

Option E is correct. The distinction between 0.5% and 0.75% bupivacaine in the obstetric setting is not pharmacodynamic — both concentrations are the same molecule with identical Nav1.5 channel-binding kinetics — but pharmacokinetic and situational. The safety concern arises specifically from accidental intravascular injection, which is a recognized risk in obstetric epidural practice because the epidural venous plexus is engorged during pregnancy, increasing the probability of inadvertent intravascular catheter placement. If a full epidural dose of 0.75% bupivacaine is injected intravenously, the resulting bolus delivers substantially more milligrams of bupivacaine to the systemic circulation per unit volume than 0.5% bupivacaine would. Given bupivacaine's fast-in, slow-out cardiac channel kinetics, this produces rapid and refractory ventricular fibrillation before the clinical warning signs of intravascular injection (tinnitus, metallic taste, circumoral numbness) can be recognized and acted upon. The FDA withdrawal in 1984 followed multiple reports of maternal deaths from exactly this mechanism. The principle established is that the highest concentration of a potent long-acting local anesthetic should not be used routinely in clinical settings where inadvertent intravascular injection is probable.

Option A: Option A is incorrect; the cardiac toxicity associated with bupivacaine 0.75% in obstetrics was caused by the bupivacaine itself following intravascular injection, not by a preservative.
Option B: Option B is incorrect; bupivacaine does not form lipid micelles at clinical concentrations, and intracellular endocytic delivery is not a mechanism of local anesthetic toxicity.
Option C: Option C is incorrect; while high thoracic sympathectomy does cause hypotension, this is not the mechanism of the fatal cardiovascular collapse associated with 0.75% bupivacaine — the deaths were caused by direct cardiac sodium channel toxicity from intravascular injection.
Option D: Option D is incorrect; bupivacaine does not undergo a concentration-dependent conformational change affecting Nav1.5 affinity; the pharmacodynamics at the channel are the same regardless of the solution concentration.

5. A 34-year-old otherwise healthy man receives prilocaine 580 mg for a prolonged regional anesthetic procedure and does not develop methemoglobinemia. A 6-week-old infant undergoing a circumcision has EMLA cream applied to approximately 40% of his body surface area and develops clinically significant methemoglobinemia at an estimated total prilocaine dose well below 600 mg. Which of the following correctly explains why the infant developed toxicity at a dose that was tolerated by the adult?

A) The infant's higher body surface area-to-volume ratio produces proportionally greater dermal absorption per kilogram of body weight, elevating plasma prilocaine concentrations above the adult threshold even at an absolutely lower total dose — the toxicity is pharmacokinetic, not pharmacodynamic.
B) Neonatal and infant erythrocytes (red blood cells) contain fetal hemoglobin (HbF), which is oxidized to methemoglobin by o-toluidine more readily than adult hemoglobin (HbA); simultaneously, neonatal methemoglobin reductase activity is functionally immature, reducing the rate at which methemoglobin is enzymatically reduced back to functional hemoglobin — both factors lower the effective threshold for clinically significant methemoglobinemia.
C) The infant's immature hepatic CYP enzymes are unable to metabolize prilocaine to o-toluidine; instead, prilocaine undergoes an alternative neonatal metabolic pathway generating a different aromatic amine metabolite with substantially greater oxidizing potency than o-toluidine.
D) EMLA cream penetrates infant skin more rapidly than adult skin because the stratum corneum is thinner in neonates; the rate of prilocaine absorption per unit time is therefore higher in infants, producing peak plasma concentrations that transiently exceed adult thresholds before the slower neonatal metabolism can clear the drug.
E) Infants have a higher proportion of body water relative to body fat compared to adults, reducing the volume of distribution of prilocaine (a lipophilic drug) and producing higher plasma concentrations per milligram dose, which in turn generate higher o-toluidine exposure and greater methemoglobin formation.

ANSWER: B

Rationale:

Option B is correct. Neonates and infants are at substantially lower threshold for prilocaine-induced methemoglobinemia for two independent and additive reasons. First, fetal hemoglobin (HbF), which predominates in neonates during the first months of life before replacement by adult hemoglobin (HbA), is more susceptible to oxidation of its iron from Fe²⁺ to Fe³⁺ by o-toluidine than adult hemoglobin. Second, and more importantly, neonatal methemoglobin reductase (NADH-cytochrome b5 reductase — the enzyme that reduces Fe³⁺ methemoglobin back to functional Fe²⁺ hemoglobin) has markedly immature activity in the first months of life, typically reaching only 50–60% of adult enzyme activity. This enzymatic immaturity means that even low rates of methemoglobin formation cannot be adequately corrected, allowing methemoglobin to accumulate to clinically significant levels at total doses that a healthy adult with fully functional methemoglobin reductase would safely clear. The same reduced threshold applies to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and those with baseline hypoxemia, where the physiologic reserve for tolerating methemoglobin elevation is already compromised.

Option A: Option A is incorrect; while the surface area-to-volume ratio is relevant to the rate of percutaneous absorption, the question specifies that the dose was below 600 mg in absolute terms — the explanation must account for increased sensitivity at an equivalent or lower absolute dose, which is pharmacodynamic, not purely pharmacokinetic.
Option C: Option C is incorrect; neonatal hepatic CYP immaturity would reduce o-toluidine production (if anything, reducing toxicity risk from the metabolic step), and there is no documented alternative neonatal metabolic pathway generating a more potent oxidizing metabolite.
Option D: Option D is incorrect; while neonatal skin barrier function is reduced, this primarily affects absorption rate and total absorbed dose, not the pharmacodynamic sensitivity to methemoglobin formation once drug is absorbed.
Option E: Option E is incorrect; prilocaine has relatively low protein binding and intermediate lipid solubility — the volume of distribution argument does not correctly predict the observed pharmacodynamic sensitivity difference.

6. A parturient at 38 weeks gestation requires urgent conversion of her labor epidural to surgical anesthesia for an emergency cesarean delivery. She has a documented history of prolonged succinylcholine effect following a prior surgery, and her preoperative workup confirms homozygous atypical pseudocholinesterase genotype with a dibucaine number of 24. The obstetric anesthesiologist reaches for chloroprocaine to exploit its rapid systemic clearance. Which of the following correctly describes how the patient's pseudocholinesterase status affects the pharmacokinetics of epidural chloroprocaine in this situation?

A) Pseudocholinesterase deficiency has no clinically significant effect on chloroprocaine pharmacokinetics in this patient because epidural chloroprocaine is absorbed slowly through the epidural fat and venous plexus, and the small amounts reaching the systemic circulation are well below the threshold at which plasma enzyme activity becomes the rate-limiting clearance step.
B) Pseudocholinesterase deficiency prolongs chloroprocaine's epidural duration of action by approximately 30–45 minutes beyond the normal 45–60 minute block, but peak plasma concentrations remain below toxic thresholds because hepatic CYP enzymes provide a compensatory alternative metabolic route for ester agents when plasma hydrolysis is impaired.
C) Pseudocholinesterase deficiency transforms chloroprocaine into a long-acting agent comparable to bupivacaine; the patient can still safely receive chloroprocaine at standard epidural doses because the prolonged plasma half-life simply extends the surgical anesthesia window rather than producing toxicity.
D) In this patient, pseudocholinesterase deficiency substantially prolongs chloroprocaine's plasma half-life — from under 60 seconds in normal individuals to potentially minutes or tens of minutes — eliminating the rapid systemic clearance that is the pharmacokinetic basis for chloroprocaine's exceptional safety at high epidural doses; the patient remains at risk for systemic local anesthetic toxicity from absorbed chloroprocaine that can no longer be rapidly destroyed in the bloodstream.
E) The homozygous atypical genotype selectively impairs chloroprocaine hydrolysis only at low plasma concentrations; at the higher plasma concentrations produced by epidural absorption, an alternative pseudocholinesterase isoform with normal kinetics becomes the dominant clearance pathway, restoring near-normal half-life at clinically relevant drug levels.

ANSWER: D

Rationale:

Option D is correct. Chloroprocaine's exceptional safety profile at the high doses used for epidural anesthesia (doses up to 800–1000 mg) rests entirely on its near-instantaneous hydrolysis by plasma pseudocholinesterase — a plasma half-life of under 60 seconds in individuals with normal enzyme activity. This rapid destruction means that chloroprocaine absorbed from the epidural space is eliminated in the bloodstream before it can accumulate to CNS or cardiac toxic concentrations. In a patient with homozygous atypical pseudocholinesterase — confirmed by a dibucaine number of 24, well within the homozygous atypical range of 20–30 — this enzyme is markedly deficient in its ability to hydrolyze substrates including chloroprocaine. The plasma half-life of chloroprocaine in such a patient extends from under 60 seconds to potentially minutes to tens of minutes, depending on the degree of residual enzyme activity. This pharmacokinetic transformation is clinically critical: a drug that was safe at doses of 800 mg because of instantaneous clearance becomes potentially toxic at those same doses when clearance is slow. The safety argument for high-dose chloroprocaine in this patient therefore no longer holds, and an alternative local anesthetic strategy should be employed.

Option A: Option A is incorrect; epidural absorption of chloroprocaine into the epidural venous plexus is significant and rapid, particularly during urgent bolus epidural dosing, and plasma hydrolysis is precisely the mechanism that prevents systemic accumulation — the deficiency is clinically very relevant.
Option B: Option B is incorrect; amide agents are metabolized by hepatic CYP enzymes, but ester agents have no significant CYP-mediated metabolic backup pathway — plasma pseudocholinesterase is the primary and essentially sole clearance mechanism for chloroprocaine.
Option C: Option C is incorrect; the consequence of prolonged half-life for chloroprocaine is not simply extended surgical anesthesia but elevated risk of systemic toxicity, because the drug was dosed at levels calibrated to its normally instantaneous clearance.
Option E: Option E is incorrect; there is no alternative pseudocholinesterase isoform that activates at higher plasma concentrations; the atypical enzyme is constitutively deficient regardless of substrate concentration.

7. Two patients scheduled for elective surgery both have family histories of prolonged neuromuscular blockade after anesthesia. Dibucaine numbers are obtained: Patient 1 returns a result of 52, and Patient 2 returns a result of 26. Both patients require a rapid sequence intubation where succinylcholine is the preferred agent. Which of the following correctly interprets these results and identifies the appropriate management decision for each patient?

A) Both patients have abnormal dibucaine numbers and should receive rocuronium with sugammadex reversal instead of succinylcholine; a dibucaine number below 70 in any patient indicates clinically meaningful pseudocholinesterase impairment that contraindicates succinylcholine use.
B) Patient 1 (dibucaine number 52) has acquired pseudocholinesterase deficiency from an unidentified cause and may receive succinylcholine with close monitoring; Patient 2 (dibucaine number 26) has normal enzyme and the family history is explained by a non-enzymatic cause of prolonged block such as phase II neuromuscular block from succinylcholine overdose.
C) Patient 1 (dibucaine number 52) is a heterozygous carrier for atypical pseudocholinesterase; succinylcholine will produce a modestly prolonged block of approximately 20–30 minutes rather than the normal 10–12 minutes, which is clinically manageable with ventilatory support. Patient 2 (dibucaine number 26) has the homozygous atypical genotype; succinylcholine should be avoided because neuromuscular blockade may persist for 4–8 hours or longer, representing an unacceptable risk in the context of elective surgery.
D) Patient 1 (dibucaine number 52) has severe acquired pseudocholinesterase deficiency from hepatic disease or pregnancy and should not receive succinylcholine; Patient 2 (dibucaine number 26) is a heterozygous carrier with mild impairment and can safely receive succinylcholine at a reduced dose of 0.5 mg/kg.
E) Both patients can receive succinylcholine because the dibucaine number measures residual enzyme activity as a percentage, and both patients retain more than 25% of normal enzyme function — which is sufficient to metabolize a standard 1.5 mg/kg succinylcholine dose within the normal 10–12 minute window.

ANSWER: C

Rationale:

Option C is correct. The dibucaine number measures the percentage inhibition of pseudocholinesterase by dibucaine under standardized conditions and is used to classify pseudocholinesterase genotype. The heterozygous carrier genotype (one normal allele, one atypical allele) produces an intermediate dibucaine number of approximately 40–60; Patient 1's result of 52 is consistent with heterozygous status. Heterozygous carriers have reduced but not absent enzyme activity; succinylcholine produces a modestly prolonged neuromuscular block of approximately 20–30 minutes rather than the usual 10–12 minutes, which is clinically manageable with ventilatory support in a controlled anesthetic setting. The homozygous atypical genotype (two atypical alleles, essentially no functional pseudocholinesterase) produces a dibucaine number of approximately 20–30; Patient 2's result of 26 is consistent with homozygous atypical status. In these patients, succinylcholine cannot be hydrolyzed by plasma pseudocholinesterase and the neuromuscular block persists for 4–8 hours or longer until the drug is eliminated by alternative minor pathways. In the elective surgery context, this represents an unacceptable risk, and a non-depolarizing agent with reversal capability (such as rocuronium with sugammadex) should be used instead. The same genotype distinction applies to ester local anesthetics: Patient 2 should not receive large doses of ester agents whose safety depends on rapid plasma hydrolysis. Option B has the interpretations inverted; a dibucaine number of 52 corresponds to heterozygous carrier status (inherited), not acquired deficiency, and a result of 26 indicates the homozygous atypical genetic variant, not normal enzyme. Option D has the genotype interpretation inverted; a result of 52 is consistent with heterozygous carrier, not severe acquired deficiency, and a result of 26 indicates homozygous atypical, not heterozygous.

Option A: Option A is incorrect; Patient 1's dibucaine number of 52 indicates heterozygous status, not a contraindication to succinylcholine — the block duration is prolonged but manageable, not life-threatening.
Option E: Option E is incorrect; the dibucaine number does not measure percentage of enzyme activity remaining — it measures percentage inhibition by dibucaine under defined conditions, and the interpretation is based on published genotype reference ranges, not on residual activity thresholds.

8. Before injecting a full epidural dose of local anesthetic, an anesthesiologist injects a test dose containing epinephrine 15 μg (typically as 3 mL of 1:200,000 epinephrine solution, often combined with lidocaine 45 mg). Which of the following correctly describes the mechanism by which this test dose detects accidental intravascular catheter placement, and the clinical endpoint that constitutes a positive result?

A) Intravenous injection of epinephrine 15 μg produces a transient but characteristic heart rate increase of 20 beats per minute or more within 45–60 seconds, caused by β₁-adrenergic receptor stimulation of the sinoatrial node; this tachycardic response to a small intravascular epinephrine bolus serves as a warning sign of catheter misplacement before the full local anesthetic dose is administered.
B) Intravenous injection of epinephrine 15 μg produces a sustained decrease in heart rate through baroreceptor-mediated vagal reflex, because the sudden rise in systemic blood pressure from α₁-adrenergic vasoconstriction activates carotid sinus baroreceptors, producing reflex bradycardia that identifies intravascular placement.
C) The epinephrine test dose works through its local anesthetic adjuvant effect rather than through systemic hemodynamic effects: intravascular injection disperses the epinephrine away from the epidural space and produces a weaker and delayed block onset; the absence of rapid epidural anesthesia within 3 minutes of injection indicates the needle or catheter is not correctly positioned.
D) Intravenous injection of the test dose lidocaine component (45 mg) produces an immediate metallic taste, tinnitus, or circumoral numbness through direct CNS effect, identifying intravascular placement; the epinephrine is included to prolong the duration of these early CNS warning symptoms, not to produce its own hemodynamic signal.
E) The 15 μg epinephrine test dose is designed to produce a transient hypertensive response through peripheral α₁-adrenergic vasoconstriction; a systolic blood pressure rise of more than 20 mmHg within 60 seconds identifies intravascular placement and distinguishes it from the blood pressure decrease that accompanies correctly placed epidural anesthesia.

ANSWER: A

Rationale:

Option A is correct. The epinephrine test dose exploits the β₁-adrenergic effect of a small intravenous epinephrine bolus on the sinoatrial node. When 15 μg of epinephrine is injected intravenously — rather than into the epidural space — it reaches the right heart and systemic circulation rapidly, producing direct β₁ stimulation of the sinoatrial node and a characteristic heart rate increase of 20 beats per minute or more, typically appearing within 45–60 seconds of injection. This tachycardic response is the classic positive test dose endpoint. Because 15 μg is a very small epinephrine dose, the heart rate response is transient (lasting 30–60 seconds) and clinically well-tolerated. When the same dose is correctly placed in the epidural space, very little reaches the systemic circulation, and the heart rate response is absent or minimal. The test dose therefore provides a window of warning between the injection of an innocuous small bolus and the injection of the full local anesthetic dose — allowing the anesthesiologist to withhold the large dose if intravascular placement is detected. It should be noted that the test dose is less reliable in patients receiving β-blockers (which blunt the tachycardic response) and in laboring patients (whose baseline heart rate variability can produce false positives).

Option B: Option B is incorrect; the endpoint is tachycardia from β₁ stimulation, not bradycardia from baroreceptor reflex — the α₁ vasoconstriction from 15 μg epinephrine IV is modest and a reflex bradycardia is not the expected or reliable endpoint.
Option C: Option C is incorrect; the test dose mechanism is hemodynamic (heart rate response to intravascular epinephrine), not based on block onset timing or quality.
Option D: Option D is incorrect; while the lidocaine component (45 mg IV) can produce CNS symptoms of local anesthetic toxicity that also signal intravascular injection, these are the signal from the lidocaine component, not from epinephrine; epinephrine's signal is the heart rate response, not prolongation of CNS symptoms.
Option E: Option E is incorrect; the classical test dose endpoint is heart rate increase (tachycardia from β₁ stimulation), not blood pressure increase — the tachycardic endpoint is more sensitive and specific than a hypertensive endpoint for detecting intravascular injection.

9. A patient undergoing a supraclavicular nerve block receives bupivacaine 0.5% and develops sudden loss of consciousness followed by refractory ventricular fibrillation within 90 seconds of injection. Standard resuscitation including epinephrine and multiple defibrillation attempts fail to restore organized rhythm after 3 minutes. The team prepares intravenous lipid emulsion therapy. Which of the following correctly describes the mechanism by which lipid emulsion rescues bupivacaine-induced cardiac arrest?

A) Intravenous lipid emulsion raises plasma pH through its alkaline formulation, shifting bupivacaine from the ionized to the unionized form; the unionized bupivacaine dissociates more readily from Nav1.5 channels, allowing cardiac conduction to recover during resuscitation.
B) The lipid emulsion provides free fatty acid substrate to ischemic cardiomyocytes, restoring mitochondrial ATP production that was inhibited by bupivacaine's direct effect on the electron transport chain — rescuing myocardial function through metabolic rather than pharmacokinetic reversal.
C) Lipid emulsion activates hepatic lipase enzymes that rapidly esterify bupivacaine in the systemic circulation, converting the active amide form to an inactive lipid-conjugated metabolite that cannot rebind cardiac sodium channels after defibrillation.
D) The lipid emulsion competitively displaces bupivacaine from plasma protein binding sites, creating a large pool of free bupivacaine that is then rapidly excreted by the kidneys through glomerular filtration of the now-unbound drug — lowering total body bupivacaine burden.
E) Intravenous lipid emulsion creates a separate lipid compartment in the bloodstream that acts as a pharmacokinetic "lipid sink," sequestering the highly lipophilic bupivacaine molecules away from cardiac sodium channels and into the intravascular lipid phase; this partitioning reduces the free bupivacaine concentration available to bind myocardial Nav1.5 channels, allowing channel recovery and restoration of cardiac conduction.

ANSWER: E

Rationale:

Option E is correct. The mechanism of lipid emulsion rescue in local anesthetic systemic toxicity (LAST) is best described by the "lipid sink" hypothesis. Intravenous lipid emulsion (20% intralipid, typically given as a 1.5 mL/kg bolus followed by infusion) creates a separate lipid phase within the bloodstream. Because bupivacaine is highly lipophilic — with a high octanol:water partition coefficient — it has a strong thermodynamic tendency to partition into the lipid phase. By providing an abundant lipid compartment, the emulsion sequesters bupivacaine molecules away from the aqueous plasma phase and away from cardiac sodium channels, reducing the free bupivacaine concentration at the Nav1.5 channel. As bupivacaine is extracted from the cardiac tissue into the lipid phase, channels recover their excitability, organized conduction can be restored, and defibrillation becomes effective. Secondary mechanisms including direct improvement of myocardial fatty acid utilization may contribute, but the pharmacokinetic lipid sink effect is the primary and best-supported mechanism. Lipid emulsion therapy is now a mandatory component of LAST management protocols and is carried in all settings where high-dose local anesthetics are administered.

Option A: Option A is incorrect; lipid emulsion formulations are not alkaline and do not shift bupivacaine's ionization state; the rescue mechanism is partitioning into the lipid phase, not pH-mediated dissociation from channels.
Option B: Option B is incorrect; while bupivacaine does have effects on mitochondrial function at high concentrations, the primary rescue mechanism of lipid emulsion is pharmacokinetic (lipid sink), not metabolic substrate provision.
Option C: Option C is incorrect; lipid emulsion does not activate hepatic lipase to metabolize bupivacaine; bupivacaine is an amide and cannot be esterified by lipase, which cleaves ester bonds in triglycerides.
Option D: Option D is incorrect; lipid emulsion does not displace bupivacaine from protein binding; the mechanism is sequestration of free drug into the lipid phase, not competition for protein binding sites.

10. A patient receiving a continuous ropivacaine epidural infusion for postoperative analgesia is also taking fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that is a potent inhibitor of CYP1A2 (cytochrome P450 1A2 — a hepatic enzyme that metabolizes certain drugs). Which of the following correctly predicts the pharmacokinetic consequence of this combination, and explains why the same interaction would be less pronounced with a continuous bupivacaine infusion?

A) Fluvoxamine inhibits CYP1A2 and CYP3A4 with equal potency; because both ropivacaine and bupivacaine depend equally on CYP3A4 and CYP1A2 for their hepatic clearance, the interaction produces equivalent plasma accumulation for both agents, and the clinical concern is identical regardless of which agent is used.
B) Ropivacaine is more dependent on CYP1A2 than bupivacaine for its hepatic clearance; fluvoxamine-mediated CYP1A2 inhibition therefore reduces ropivacaine clearance more substantially than bupivacaine clearance, producing higher ropivacaine plasma concentrations at steady state and a narrowed margin between therapeutic infusion concentrations and systemic toxicity thresholds.
C) Fluvoxamine inhibits the hepatic uptake transporter OATP1B1 (organic anion transporting polypeptide 1B1), which is responsible for delivering ropivacaine to hepatic CYP enzymes; reduced transporter activity lowers the intrahepatic ropivacaine concentration and paradoxically reduces CYP-mediated metabolite formation, lowering systemic toxicity risk during the infusion.
D) The interaction is clinically significant for bupivacaine but not for ropivacaine; bupivacaine is primarily metabolized by CYP1A2 and its clearance is substantially reduced by fluvoxamine, whereas ropivacaine relies almost exclusively on CYP3A4, which is not meaningfully inhibited by fluvoxamine at therapeutic doses.
E) Fluvoxamine increases CYP1A2 expression through PXR (pregnane X receptor) nuclear receptor activation; the resulting CYP1A2 induction accelerates ropivacaine metabolism and reduces plasma concentrations below steady state levels, producing under-analgesia rather than toxicity during continuous infusion.

ANSWER: B

Rationale:

Option B is correct. Both ropivacaine and bupivacaine are amide local anesthetics metabolized by hepatic cytochrome P450 enzymes, principally CYP3A4 and CYP1A2. However, the relative dependence on each isoform differs between the two agents. Ropivacaine is substantially more dependent on CYP1A2 for its primary metabolic clearance than bupivacaine, which relies more heavily on CYP3A4. Fluvoxamine is a potent and selective CYP1A2 inhibitor at therapeutic antidepressant doses. In a patient receiving a continuous ropivacaine infusion, fluvoxamine-mediated CYP1A2 inhibition significantly reduces ropivacaine's hepatic clearance, leading to progressive accumulation of ropivacaine plasma concentrations toward and potentially beyond the threshold for systemic toxicity. The same interaction with bupivacaine produces a less pronounced effect because bupivacaine's clearance is less dependent on CYP1A2. This clinically important interaction underscores the need to review concomitant medications before initiating continuous amide local anesthetic infusions. Ciprofloxacin, another CYP1A2 inhibitor, produces a similar interaction with ropivacaine. Smoking induces CYP1A2 and modestly accelerates ropivacaine clearance — the inverse interaction. Option D has the CYP isoform dependence inverted; ropivacaine is more CYP1A2-dependent than bupivacaine, not less.

Option A: Option A is incorrect; fluvoxamine is a selective CYP1A2 inhibitor and is not a potent CYP3A4 inhibitor at therapeutic doses; the two agents are not equally affected because their CYP1A2 dependence differs.
Option C: Option C is incorrect; the mechanism described — OATP1B1 transporter inhibition reducing intrahepatic drug delivery — is not the relevant interaction for ropivacaine and fluvoxamine; ropivacaine clearance is enzyme-limited, not transporter-limited in this context.
Option E: Option E is incorrect; fluvoxamine inhibits CYP1A2, it does not induce it; CYP induction is mediated by nuclear receptors such as AhR (aryl hydrocarbon receptor) for CYP1A2, not by fluvoxamine, which is an inhibitor.

11. An otolaryngologist requests cocaine hydrochloride 4% solution for topical nasal mucosal anesthesia and vasoconstriction prior to endoscopic sinus surgery in a 70 kg adult patient with no significant comorbidities. Which of the following correctly identifies the maximum safe dose for this application and the pharmacologic reason cocaine is absolutely restricted to topical use?

A) The maximum topical dose of cocaine is 10 mg/kg (700 mg in this patient); cocaine is restricted to topical use because its ester-class structure requires mucosal pseudocholinesterase for activation, and this enzymatic activation step does not occur in subcutaneous tissue, making injected cocaine pharmacologically inert.
B) The maximum topical dose of cocaine is 5 mg/kg (350 mg in this patient); cocaine is restricted to topical use because injected cocaine produces instantaneous systemic uptake that overwhelms plasma pseudocholinesterase capacity, whereas mucosal application allows slower absorption that can be cleared before toxic concentrations are reached.
C) The maximum topical dose of cocaine is approximately 1.5–3 mg/kg with a practical ceiling of approximately 200 mg in healthy adults (105–210 mg for this patient, with 200 mg as the absolute maximum); cocaine is restricted to topical use because subcutaneous or intravascular injection bypasses the rate-limiting step of mucosal absorption, producing immediate high peak plasma concentrations, direct cardiac sodium channel blockade, and catecholamine accumulation from norepinephrine reuptake inhibition — a combination that produces rapid cardiovascular toxicity without the partial buffering provided by the mucosal absorption barrier.
D) The maximum topical dose of cocaine is 1 mg/kg (70 mg in this patient); cocaine is restricted to topical use because the cocaine molecule undergoes structural modification at physiologic tissue pH when injected subcutaneously, producing a toxic free-base precipitate that cannot be cleared by normal metabolic pathways.
E) There is no established maximum dose for topical cocaine because the drug is metabolized instantaneously by nasal mucosal pseudocholinesterase and never reaches significant systemic concentrations; the restriction to topical use reflects regulatory classification as a Schedule II controlled substance rather than any pharmacologic safety concern with the injection route.

ANSWER: C

Rationale:

Option C is correct. The maximum recommended topical dose of cocaine is approximately 1.5–3 mg/kg with a practical ceiling of approximately 200 mg in healthy adults — for this 70 kg patient, the weight-based range yields 105–210 mg, with 200 mg as the accepted upper limit. This conservative maximum reflects cocaine's dual toxic profile: direct cardiovascular sodium channel blockade (identical to other local anesthetics) combined with norepinephrine reuptake inhibition producing catecholamine accumulation and sympathomimetic toxicity. Cocaine is restricted to topical use because mucosal absorption from the nasal or oropharyngeal mucosa provides a degree of rate-limiting absorption — the drug is absorbed gradually rather than instantaneously, giving plasma clearance mechanisms time to handle the absorbed load. Subcutaneous injection or intravascular injection bypasses this absorption barrier entirely, delivering the full dose to the systemic circulation immediately and generating peak plasma concentrations that simultaneously activate both toxic mechanisms — cardiac sodium channel blockade and catecholamine surge — without time for any buffering. The combination produces a uniquely dangerous toxicity profile that is more difficult to manage than either mechanism alone. In addition to this route restriction, cocaine is contraindicated in patients with cardiovascular disease and in those receiving monoamine oxidase inhibitors (MAOIs).

Option A: Option A is incorrect; 10 mg/kg is far above the accepted maximum topical dose, and cocaine is not activated by mucosal pseudocholinesterase — the restriction to topical use is pharmacokinetic (absorption rate), not based on enzymatic activation.
Option B: Option B is incorrect; 5 mg/kg is above the accepted maximum, and the explanation conflates pseudocholinesterase capacity saturation with the actual absorption-rate mechanism.
Option D: Option D is incorrect; 1 mg/kg is more conservative than necessary for topical use, and cocaine does not precipitate as a toxic free-base at physiologic tissue pH.
Option E: Option E is incorrect; cocaine does have a well-established maximum topical dose, and there is genuine pharmacologic danger with injection — the restriction is not merely regulatory.

12. A regional anesthesiologist is planning a continuous popliteal sciatic nerve block for postoperative analgesia after foot surgery. She wants to add dexamethasone to extend the single-injection component of the block but is uncertain whether to administer it perineurally or intravenously. Which of the following correctly summarizes the evidence comparing these routes and identifies the preferred approach in current practice?

A) Perineural dexamethasone is substantially more effective than intravenous dexamethasone for extending peripheral nerve block duration; meta-analyses consistently demonstrate a 12–14 hour additional benefit for the perineural route compared to IV, making perineural administration the strongly preferred route whenever nerve block duration extension is the primary goal.
B) Intravenous dexamethasone at 4 mg is the only route with proven efficacy for extending peripheral nerve block duration; perineural dexamethasone has not been shown to extend block duration beyond the effect of the local anesthetic alone in randomized controlled trials, and its use perineurally represents off-label administration without supporting evidence.
C) The two routes are equivalent in duration-extending efficacy, and perineural administration is preferred over IV because the local concentration at the nerve allows lower total doses to be used — reducing systemic steroid exposure while achieving the same analgesic benefit.
D) Meta-analyses demonstrate that perineural and intravenous dexamethasone (8 mg IV) are approximately equivalent in their peripheral nerve block duration-extending effect of approximately 6–8 hours; because the benefit is largely equivalent between routes, and because the long-term effects of repeated perineural corticosteroid exposure on neural tissue are not fully characterized, many practitioners prefer the intravenous route to avoid uncertain local neural effects while retaining the same analgesic benefit.
E) Dexamethasone extends peripheral nerve block duration only when administered at the time of block placement; intravenous dexamethasone given more than 30 minutes before or after block injection has no effect on block duration because the therapeutic window for glucocorticoid-nerve interaction is limited to the period of active local anesthetic channel binding.

ANSWER: D

Rationale:

Option D is correct. Multiple randomized controlled trials and meta-analyses have examined the comparative efficacy of perineural versus intravenous dexamethasone for extending peripheral nerve block duration. The consistent finding is that both routes produce approximately equivalent block duration extension of approximately 6–8 hours when added to intermediate- or long-acting local anesthetics. This equivalence has a significant clinical implication: because the analgesic benefit is similar regardless of route, the choice between routes can be made on safety grounds rather than efficacy grounds. The long-term effects of repeated perineural corticosteroid injections on peripheral nerve histology and function are not fully characterized — animal studies have raised concerns about potential neurotoxicity with repeated exposure, though single-dose clinical use has not demonstrated clear harm. Given this uncertainty, many practitioners prefer intravenous administration (typically 8 mg dexamethasone IV at induction of anesthesia) to achieve equivalent block prolongation while avoiding any potential local neural effects. The mechanisms by which dexamethasone extends block duration are likely multiple: suppression of inflammatory sensitization, direct inhibition of nociceptive C-fiber discharge, and systemic anti-inflammatory effects.

Option A: Option A is incorrect; meta-analyses do not demonstrate a 12–14 hour superiority of perineural over IV dexamethasone — the routes are approximately equivalent in their duration-extending effect.
Option B: Option B is incorrect; both perineural and IV routes have demonstrated efficacy in randomized trials and meta-analyses; the statement that perineural use is unsupported is incorrect.
Option C: Option C is incorrect; the preference for one route over the other is not based on lower total dose requirements — the standard IV dose (8 mg) is not substantially different from the perineural dose (4–8 mg), and the rationale for preferring IV in current practice is safety (neural tissue concerns), not dose minimization.
Option E: Option E is incorrect; there is no established narrow therapeutic window for dexamethasone's block-prolonging effect relative to block placement timing — the effect is not dependent on simultaneous administration with local anesthetic injection.

13. Both mepivacaine and bupivacaine 0.75% are avoided in obstetric epidural practice, but for different pharmacologic reasons. Which of the following correctly pairs each drug with its specific mechanism of obstetric concern?

A) Mepivacaine is avoided in labor epidural analgesia because it crosses the placenta in significant quantities and neonatal hepatic CYP enzyme systems are too immature to clear it efficiently, producing prolonged neonatal central nervous system depression; bupivacaine 0.75% is avoided because this concentration delivers a potentially lethal milligram load if accidentally injected intravascularly into the engorged epidural venous plexus, producing rapid and refractory cardiac toxicity from its slow-dissociation Nav1.5 channel kinetics.
B) Mepivacaine is avoided because it directly stimulates uterine smooth muscle contractions, producing tetanic uterine contractions that compromise uteroplacental perfusion during labor; bupivacaine 0.75% is avoided because it produces excessive motor blockade at this concentration, impairing the maternal expulsive effort during the second stage of labor.
C) Both drugs are avoided for the same fundamental reason — high placental transfer ratios leading to fetal accumulation — but bupivacaine's placental transfer is concentration-dependent and only problematic at 0.75%, while mepivacaine's placental transfer occurs at all concentrations including the dilute solutions used for labor analgesia.
D) Mepivacaine is avoided because its o-toluidine metabolite (formed by neonatal hepatic metabolism) produces methemoglobinemia in neonates after placental transfer and neonatal exposure; bupivacaine 0.75% is avoided because the high concentration produces disproportionately greater placental transfer than 0.5% bupivacaine, delivering toxic fetal concentrations.
E) Mepivacaine is avoided because it inhibits neonatal pseudocholinesterase, impairing the neonate's ability to metabolize ester-class drugs administered in the delivery room; bupivacaine 0.75% is avoided because obstetric patients have lower plasma protein binding capacity due to dilutional hypoproteinemia, making the free-fraction toxicity of 0.75% bupivacaine disproportionately high.

ANSWER: A

Rationale:

Option A is correct. The obstetric concerns for mepivacaine and bupivacaine 0.75% are distinct and reflect different pharmacologic mechanisms. Mepivacaine crosses the placenta in clinically meaningful amounts, and once in the fetal circulation, it cannot be efficiently cleared by the neonate because neonatal hepatic CYP enzyme systems are immature at birth — neonates have substantially reduced CYP activity compared to adults. The result is prolonged plasma mepivacaine concentrations in the neonate producing dose-dependent central nervous system depression and neurobehavioral suppression. This concern led to the removal of mepivacaine from obstetric epidural practice in the 1960s and 1970s following clinical reports of neonatal depression disproportionate to maternal plasma levels. Bupivacaine's obstetric concern is entirely different: bupivacaine at low concentrations (0.0625–0.25%) is the current standard for labor epidural analgesia because its high protein binding limits placental transfer and its direct neonatal toxicity is low. The contraindication for 0.75% bupivacaine is maternal, not fetal — specifically the risk of fatal cardiovascular collapse from inadvertent intravascular injection of the concentrated preparation into the engorged epidural venous plexus, producing a lethal bupivacaine bolus to the maternal heart.

Option B: Option B is incorrect; mepivacaine does not stimulate uterine contractions, and 0.75% bupivacaine's contraindication is cardiovascular toxicity from intravascular injection, not motor blockade.
Option C: Option C is incorrect; the two drugs are avoided for different reasons, not the same reason; and bupivacaine placental transfer is actually low at all clinical concentrations due to high protein binding — fetal transfer is not the mechanism of the 0.75% contraindication.
Option D: Option D is incorrect; mepivacaine does not produce an o-toluidine metabolite — that is prilocaine's metabolite and the basis for prilocaine-induced methemoglobinemia; mepivacaine's concern is neonatal CYP clearance.
Option E: Option E is incorrect; mepivacaine does not inhibit neonatal pseudocholinesterase, and the 0.75% bupivacaine contraindication is not explained by dilutional hypoproteinemia in pregnancy.

14. Sodium bicarbonate is sometimes added to local anesthetic solutions to accelerate onset by alkalinizing the solution and shifting the ionization equilibrium toward the free-base form. For which clinical application is the evidence for bicarbonate-mediated onset acceleration most robust, and why is the same benefit less consistently demonstrated in other applications?

A) The evidence is strongest for peripheral nerve blocks with bupivacaine; because bupivacaine has the highest pKa (8.1) of the commonly used amides, the ionization shift produced by bicarbonate alkalinization produces a proportionally larger increase in free-base fraction for bupivacaine than for lower-pKa agents, and this larger ionization shift translates into a clinically meaningful onset acceleration of 8–10 minutes.
B) The evidence is strongest for spinal anesthesia with hyperbaric bupivacaine; bicarbonate raises the pH of the spinal solution above cerebrospinal fluid pH, producing a free-base precipitation that settles by gravity into the dependent areas of the subarachnoid space, concentrating drug at the target spinal cord segments and dramatically accelerating the onset of intrathecal blockade.
C) The evidence is equally strong across all routes and agents; the mechanism of bicarbonate-mediated onset acceleration is purely physicochemical and does not depend on the specific clinical application, anatomic site, or local anesthetic agent used — bicarbonate invariably accelerates onset by the same proportional amount wherever it is used.
D) The evidence is strongest for topical anesthesia with lidocaine gel on mucosal surfaces; the alkaline pH produced by bicarbonate prevents the ionization of lidocaine in the mucus layer overlying mucosal surfaces, allowing faster penetration through the mucus barrier to underlying sensory nerve endings.
E) The evidence for onset acceleration is strongest for epidural anesthesia with lidocaine, where randomized trials consistently demonstrate a reduction in epidural onset time of approximately 2–5 minutes; the benefit in peripheral nerve blocks is weaker and less consistent across studies, likely because tissue buffering capacity at peripheral injection sites rapidly overcomes the exogenous alkalinization, restoring the local pH toward physiologic values before meaningful additional free-base drug can reach the nerve.

ANSWER: E

Rationale:

Option E is correct. The clinical evidence for bicarbonate-mediated onset acceleration in local anesthesia is context-dependent. The most consistent and reproducible benefit has been demonstrated for epidural anesthesia with lidocaine, where multiple randomized controlled trials have shown an onset acceleration of approximately 2–5 minutes — a clinically meaningful reduction when obstetric or urgent surgical epidural conversions are being performed. The epidural space, which is relatively enclosed and has limited buffering capacity, may maintain the alkalinized pH of the injected solution long enough for the ionization shift to produce a meaningful increase in free-base drug reaching epidural nerve roots. In contrast, the benefit in peripheral nerve blocks is inconsistent across trials — some studies show modest acceleration, others show no difference. The likely explanation is that the abundant tissue buffering capacity at peripheral injection sites (from bicarbonate/CO₂ equilibrium in tissue fluid, protein buffering, and cellular buffering systems) rapidly neutralizes the exogenous alkalinization, restoring local pH toward 7.4 before the full theoretical ionization shift can be realized. Bicarbonate alkalinization does not alter block quality or duration in either setting, and its benefit in any individual clinical scenario must be weighed against the preparation inconvenience and the risk of bupivacaine precipitation if excessive bicarbonate concentrations are used (bupivacaine precipitates at alkaline pH more readily than lidocaine).

Option A: Option A is incorrect; bupivacaine's high pKa does mean that a given pH shift produces a larger proportional increase in free-base fraction, but the clinical evidence for bicarbonate benefit is specifically stronger for epidural lidocaine, not for peripheral bupivacaine blocks.
Option B: Option B is incorrect; adding bicarbonate to hyperbaric spinal solutions is not standard practice, and precipitation of free-base bupivacaine in the subarachnoid space would be a safety concern rather than a benefit.
Option C: Option C is incorrect; the evidence is not equally strong across all applications — the epidural lidocaine application has the strongest evidence, while peripheral nerve block evidence is inconsistent.
Option D: Option D is incorrect; topical mucosal alkalinization is not the setting with the strongest clinical evidence for bicarbonate benefit, and the mechanism described is not the established one.

15. Tetracaine 15 mg intrathecally produces reliable surgical spinal anesthesia for a hip replacement, yet tetracaine is never used for femoral or sciatic peripheral nerve blocks where total doses of 100–200 mg are routinely used with other agents. Which of the following correctly explains why the same molecule that is safe at 15 mg intrathecally becomes unacceptably dangerous at the doses required for peripheral nerve blockade?

A) Tetracaine is only pharmacologically active in the intrathecal space because cerebrospinal fluid (CSF) contains a specific esterase enzyme that cleaves tetracaine into an active metabolite; in the peripheral tissue environment, tetracaine remains in its prodrug form and is pharmacologically inert, which is why it is not used peripherally.
B) Tetracaine produces neurotoxic concentrations in peripheral nerve myelin at doses above 20 mg; because peripheral nerve blocks require 100–200 mg, tetracaine invariably causes permanent axonal demyelination at peripheral injection sites, which is not a concern for intrathecal use because the nerve roots in the subarachnoid space lack myelin.
C) Tetracaine's high potency means that the milligram doses required to achieve adequate block volume and concentration for peripheral nerve anesthesia would substantially exceed the threshold for systemic cardiovascular and CNS toxicity; the 5–20 mg intrathecal dose is effective because the drug is confined to the subarachnoid space without systemic absorption, whereas the 100–200 mg required for peripheral block would produce toxic systemic plasma concentrations upon vascular absorption from peripheral tissue.
D) Tetracaine is not used for peripheral nerve blocks because it is a solid crystalline powder at room temperature and cannot be dissolved to the high-volume, low-concentration solutions needed for peripheral nerve block injection; its limited aqueous solubility prevents preparation of the dilute solutions required for large-volume nerve block techniques.
E) Tetracaine undergoes rapid metabolism by Schwann cell (myelin-forming cell) esterases at peripheral nerve sheaths, which destroys the drug before it can penetrate to the axon; the intrathecal space lacks Schwann cells and this enzymatic barrier, allowing tetracaine to reach axonal sodium channels at doses that would be inactivated at peripheral sites.

ANSWER: C

Rationale:

Option C is correct. The fundamental reason tetracaine is safe intrathecally but unsafe at peripheral block doses is the combination of its very high potency and the route-specific pharmacokinetics of each technique. Tetracaine is approximately 10 times more potent than procaine and highly potent compared to lidocaine — its minimum effective concentration for nerve blockade is low, meaning small milligram quantities produce profound anesthesia. For spinal anesthesia, the drug is delivered directly into the subarachnoid space bathing the nerve roots, where it distributes in a small volume of cerebrospinal fluid (CSF) with minimal systemic absorption. The 5–20 mg dose that provides reliable spinal anesthesia therefore represents a very low total body exposure, and systemic plasma concentrations remain far below toxic thresholds. To block a large peripheral nerve such as the femoral or sciatic, the drug must diffuse across multiple tissue barriers — fascia, epineurium, perineurium — and the volume and concentration required to achieve this would demand doses of 100–200 mg for most other agents. At tetracaine's potency, the concentration needed for peripheral block could be achieved at lower milligram quantities, but the volume required to spread the drug around the nerve still demands a total dose that, once absorbed from the vascularized peripheral tissue bed, would produce toxic systemic plasma concentrations. The therapeutic window — the ratio of effective dose to toxic dose — is too narrow to permit safe peripheral nerve block dosing with tetracaine.

Option A: Option A is incorrect; there is no specific CSF esterase that activates tetracaine into a metabolite; tetracaine is active in its unmodified form and is an ester hydrolyzed by plasma pseudocholinesterase after systemic absorption.
Option B: Option B is incorrect; tetracaine does not cause selective myelin demyelination at clinical doses, and spinal nerve roots do have myelin (albeit less compact than peripheral nerve myelin).
Option D: Option D is incorrect; tetracaine is available in aqueous solution and solubility is not the limiting factor in its clinical use profile.
Option E: Option E is incorrect; Schwann cells do not contain esterases that enzymatically inactivate tetracaine at peripheral nerve sheaths — this is not a real pharmacologic mechanism.

16. A patient is receiving a continuous epidural infusion of bupivacaine 0.1% at 10 mL/hour (delivering 10 mg/hour) for thoracic postoperative analgesia. The anesthesiologist decides to switch to ropivacaine for the remainder of the infusion due to concerns about cumulative bupivacaine exposure in the setting of mild hepatic impairment. If she wishes to deliver approximately equivalent analgesic effect, which of the following correctly applies the known potency relationship between ropivacaine and bupivacaine to select an appropriate ropivacaine dose?

A) Ropivacaine and bupivacaine are equianalgesic on a milligram-per-milligram basis for epidural use; the infusion should be switched to ropivacaine 0.1% at 10 mL/hour (10 mg/hour) to deliver identical analgesic effect.
B) Ropivacaine has approximately 60–75% of the analgesic potency of bupivacaine on a milligram basis for epidural analgesia; to deliver equivalent analgesia, the ropivacaine dose should be increased to approximately 13–17 mg/hour — achievable with ropivacaine 0.2% at 7–8 mL/hour or ropivacaine 0.15% at 10 mL/hour — while remaining within ropivacaine's safe maximum infusion dose guidelines.
C) Ropivacaine is approximately twice as potent as bupivacaine on a milligram basis; the infusion should be reduced to ropivacaine 0.05% at 10 mL/hour (5 mg/hour) to avoid exceeding the analgesic equivalence of the original bupivacaine regimen and prevent motor blockade from excessive ropivacaine dose.
D) Ropivacaine's potency relative to bupivacaine varies unpredictably between patients based on individual CYP1A2 activity; no fixed conversion ratio exists, and the infusion rate should be titrated empirically starting at a 50% dose reduction and increasing by 20% increments every 4 hours based on pain scores.
E) Ropivacaine potency is equivalent to bupivacaine for motor block but substantially lower for sensory block, with a sensory potency ratio of approximately 30–40%; to achieve equivalent sensory analgesia the ropivacaine infusion rate must be increased by at least 2.5- to 3-fold, delivering approximately 25–30 mg/hour of ropivacaine.

ANSWER: B

Rationale:

Option B is correct. Ropivacaine has approximately 60–75% of the analgesic potency of bupivacaine when compared on a milligram-per-milligram basis for epidural analgesia. This potency difference is well-established from multiple dose-finding studies and reflects ropivacaine's slightly lower lipid solubility compared to bupivacaine, which results in somewhat less avid neural membrane penetration at equivalent concentrations. The practical implication for this clinical scenario is that switching from bupivacaine 10 mg/hour to an equipotent ropivacaine dose requires delivering approximately 13–17 mg/hour of ropivacaine (the range reflecting the uncertainty within the 60–75% potency estimate). This can be achieved at the same infusion volume by increasing the ropivacaine concentration (for example, 0.15% ropivacaine at 10 mL/hour delivers 15 mg/hour), or at the same concentration by increasing the infusion rate modestly. It is worth noting that ropivacaine's maximum recommended epidural infusion rate is typically cited as 20–28 mg/hour, so the equivalent dose range is well within safe limits. This potency difference is also why ropivacaine's maximum dose guidelines on a milligram-per-kilogram basis are somewhat higher than bupivacaine's — to achieve equivalent clinical effect, more milligrams of ropivacaine must be administered.

Option A: Option A is incorrect; ropivacaine and bupivacaine are not equianalgesic on a mg-per-mg basis — ropivacaine is less potent, and substituting at the same milligram dose would deliver subequivalent analgesia.
Option C: Option C is incorrect; ropivacaine is less potent than bupivacaine, not more potent; describing it as twice as potent and halving the dose would produce severe under-analgesia.
Option D: Option D is incorrect; while CYP1A2 variability does affect ropivacaine clearance and steady-state plasma concentrations, the analgesic potency ratio between ropivacaine and bupivacaine at the nerve is a pharmacodynamic property of the molecule that does not vary with individual CYP1A2 activity — a fixed conversion ratio of approximately 60–75% is clinically applicable.
Option E: Option E is incorrect; ropivacaine's lower potency relative to bupivacaine applies to both sensory and motor block — it is not selectively weaker for sensory block only, and a 2.5- to 3-fold dose increase would substantially overshoot the required adjustment.